Skip to main content

Table 2 Base-Case Value and Sensitivity Range for Costs

From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Variables Base case value Range
Costs in China($)
Monthly cost of sorafenib and TACE
 Full-dose Sorafenib
  The first 3 months without supportive policy48 7600.38 3800.19–15,200.76
  3 months after48 15.06 7.53–30.11
 Dose-adjusted Sorafenib
  The first 3 months without supportive policy48 3807.72 1903.86–7615.43
  3 months after48 15.06 8.03–32.11
TACE per session 3347.97 1673.99.23–6695.95
Monthly cost of progressive HCC# 247.43 123.71–494.86
Monthly cost of decompensated cirrhosisa,b 1131.82 565.91–2263.65
Monthly cost of compensated cirrhosisa,b 344.14 172.07–688.29
Costs in the USA($)
Monthly cost of sorafenib and TACE
 Full-dose Sorafenib
  The first 3 months without supportive policy50 4592.4 2296.2–9184.8
  3 months after50 1.2 0.60–2.40
 Dose-adjusted Sorafenib
  The first 3 months without supportive policy50 2296.2 1148.10–4592.40
  3 months after50 1.2 0.60–2.40
TACE per session49 25,961.00 12,980.50–51,922.0
Monthly cost of progressive HCC51# 8072 4036.00–16,144.00
Monthly cost of decompensated cirrhosis49# 1519.0 759.50–3038.00
Monthly cost of compensated cirrhosis49# 61.0 30.0–122.00
  1. aThe data were obtained from the large HCC database of South China (http://hcc.medidata.cn/)
  2. bThe total monthly cost of drugs and procedures (that include treatments for HCC, cirrhosis and adverse events derived from associated drugs and procedures), inpatient and outpatient visits, laboratory testing and imaging examination